Paltusotine (formerly known as CRN00808) is a first in class, once daily oral nonpeptide selective agonist of somatostatin receptor type 2 (SST2), which is the most expressed receptor in somatotropinomas together with somatostatin receptor type 5 (SST5) (14, 15). This evidence concerns the gene SSTR5 and growth hormone-producing pituitary gland neoplasm.